Immune Checkpoint Inhibitors

Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies.

Also Known As:

Blockade, PD-1-PD-L1; CTLA 4 Inhibitor; CTLA 4 Inhibitors; Checkpoint Blockade, Immune; Checkpoint Blockers, Immune; Checkpoint Inhibition, Immune; Checkpoint Inhibitor, Immune; Checkpoint Inhibitors, Immune; Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor; Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors; Inhibitor, PD-1; PD 1 Inhibitor; PD 1 Inhibitors; PD 1 PD L1 Blockade; PD L1 Inhibitor; PD L1 Inhibitors; Programmed Death Ligand 1 Inhibitors; CTLA-4 Inhibitor; CTLA-4 Inhibitors; Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor; Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors; Immune Checkpoint Blockade; Immune Checkpoint Blockers; Immune Checkpoint Inhibition; Immune Checkpoint Inhibitor; PD-1 Inhibitor; PD-1 Inhibitors; PD-1-PD-L1 Blockade; PD-L1 Inhibitor; PD-L1 Inhibitors; Programmed Cell Death Protein 1 Inhibitor; Programmed Cell Death Protein 1 Inhibitors; Programmed Death-Ligand 1 Inhibitors

Chemical Actions and Uses
- Pharmacologic Actions: 164
  - Therapeutic Uses: 49043
    - Antineoplastic Agents: 21151
      - Immunological Antineoplastic Agents: 2
        Immune Checkpoint Inhibitors: 25068
  - Molecular Mechanisms of Pharmacological Action: 26
    - Immune Checkpoint Inhibitors: 25068

Hiroko Kadota Selected Research

Hiroko Kadota Research Topics

Disease

Drug/Important Bio-Agent (IBA)